#HAE #Argo Biopharma #BW-20805

Argo Biopharma Receives FDA Fast Track Designation for BW-20805

In a significant breakthrough for hereditary angioedema (HAE) treatment, Argo Biopharma has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational small interfering RNA (siRNA) therapy, BW-20805. This advancement underscores the innovative therapeutic approaches being utilized in combating HAE, a rare genetic condition characterized by unpredictable episodes of severe swelling.

Understanding HAE and the Development of BW-20805

Hereditary angioedema affects approximately 1.5 individuals per 100,000 people worldwide and is marked by life-threatening swelling that can occur unexpectedly. This condition is linked to a deficiency in a protein known as C1 inhibitor, leading to the uncontrolled production of bradykinin, which causes swelling. Current prophylactic treatments necessitate frequent dosing and are not always effective, creating a pressing need for long-lasting therapeutic options.

Argo Biopharma's BW-20805 works by targeting prekallikrein (PKK), a critical component in the pathway that leads to swelling. By inhibiting the expression of the PKK gene, BW-20805 holds the potential to provide a more effective and extended prevention of HAE attacks. This novel therapy aims not only to reduce the frequency of attacks but also to improve patients' quality of life significantly.

Clinical Trials and Data Supporting BW-20805

Currently, a global Phase II open-label study is ongoing with adult HAE patients, and Argo Biopharma anticipates the study will conclude its primary phase in the latter half of 2026. Data from the study, including findings presented at the AAAAI Annual Meeting, indicate promising results with significant plasma PKK reduction and a remarkable decrease in time-normalized HAE attack rates. These results bolster the potential of BW-20805 as a groundbreaking option for individuals suffering from this debilitating condition.